The treatment of hepatitis C virus (HCV) infection is possible in patients who have been successfully treated for hepatocellular carcinoma (HCC), and the best results were achieved with the use of multiple direct-acting antivirals (DAAs) and ribavirin (RBV), according to new findings published in the European Journal of Gastroenterology & Hepatology. However, HCC recurrence was noted to be high and was observed in 42% of patients. In this study group, 80.7% had recurrence within 6 months of treatment initiation.
Treatment of HCV in patients with advanced liver disease became a reality with the advent of DAA regimens. The current study describes the results of HCV treatment with DAAs in 62 patients with HCC who achieved a complete radiologic response after treatment of cancer.
Patients received one of 4 HCV treatment regimens: group 1 was given sofosbuvir (SOF)+RBV for 24 weeks, group 2 was given SOF+simeprevir for 12 weeks, group 3 received SOF+daclatasvir (DAC) for 24 weeks, and group 4 received SOF+DAC+RBV for 12 weeks.